MAP2K7 and plexiform neurofibroma: For example, a preclinical trial of the MEK inhibitor selumetinib in the Dhh-Cre;Nf1flox/flox GEMM showed pharmacokinetic results similar to those in humans with subsequent decreases in baseline neurofibroma tumor volume in 67% of animals by volumetric magnetic resonance imaging (MRI) [90].